Module 1 - Administrative information application form
Harmonised Technical Guidance (see above). Which language should be used in the application form? English should be used for a centralised procedure. English should be used for a mutual recognition or decentralised procedure.
Download Module 1 - Administrative information application form
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Harmonised Technical Guidance for Non-eCTD electronic ...
esubmission.ema.europa.euTechnical NeeS Guidance v4.0 Page 1 of 19. Guidance for Industry on Providing Regulatory Information in Electronic Format . Harmonised Technical Guidance for . Non-eCTD electronic Submissions (NeeS) for human medicinal products in the EU . Version 4.0 October 2013
EN 301 893 - V2.1.1 - 5 GHz RLAN; Harmonised Standard ...
www.etsi.orgETSI EN 301 893 V2.1.1 (2017-05) 5 GHz RLAN; Harmonised Standard covering the essential requirements of article 3.2 of Directive 2014/53/EU HARMONISED EUROPEAN STANDARD
Special Condition for small-category VTOL aircraft
www.easa.europa.euThe special condition has been established to prescribe the technical specifications for the type certification of a person-carrying vertical take-off and landing (VTOL) heavier-than-air aircraft in the small category, with lift/thrust units used to generate powered lift and control.
ICH HARMONISED TRIPARTITE GUIDELINE
database.ich.orgICH Harmonised Tripartite Guideline Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 10 November 2000, this guideline is recommended for adoption to the three regulatory parties to ICH TABLE OF CONTENTS 1.
ICH HARMONISED TRIPARTITE GUIDELINE
database.ich.orgprocess of the drug substance, and also provides guidance on what information should be provided in Module 3 of the Common Technical Document (CTD) Sections 3.2.S.2.2 – 3.2.S.2.6 (ICH M4Q). It addresses aspects of development and manufacture that pertain to drug substance, including the presence of steps designed to reduce impurities. In
ICH guideline Q9 (R1) on quality risk management
www.ema.europa.euICH Q9(R1) Guideline 2 33 scenarios, so that appropriate risk control can be decided upon during technology transfer, for 34 use during the commercial manufacturing phase. In this context, knowledge is used to make 35 informed risk-based decisions, trigger re-evaluations and stimulate continual improvements. 36 Effective and proactive quality risk management can facilitate …